文献速递核素与放射性配体治疗肿瘤 PET/CT

[225Ac]Ac-DOTATOC α疗法在胰腺神经内分泌肿瘤肝微转移临床前模型中的生存影响

Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-09-13

在模拟胰腺神经内分泌肿瘤肝微转移的小鼠模型中,评价[225Ac]Ac-DOTATOC的疗效与毒性。所有治疗组总生存期较未标记DOTATOC组显著延长,最高活度组达53天(240 kBq)和58天(2×120 kBq),对照组28天;血液学毒性为一过性白细胞中度下降,未见严重肝肾功能毒性。

要点

  • 肝肿瘤模型显示[68Ga]Ga-DOTATOC高摄取而[18F]F-FDG无摄取,证实为高分化表型。
  • 240 kBq组中位总生存53天(p=0.0001),2×120 kBq组58天(p<0.0001),对照组28天。
  • 治疗后出现一过性白细胞中度下降,未观察到严重肝、肾毒性。

核心结论

  • [225Ac]Ac-DOTATOC在胰腺神经内分泌肿瘤肝微转移小鼠模型中表现出有利的疗效与毒性特征。

研究设计与样本

  • 临床前小鼠模型研究:经门静脉注射AR42J细胞建立胰腺神经内分泌肿瘤肝转移模型,用[68Ga]Ga-DOTATOC和[18F]F-FDG PET/MRI评估;在皮下瘤NMRI裸鼠中测定[225Ac]Ac-DOTATOC的生物分布与辐射剂量学;门静脉移植后10天静脉注射递增活度的[225Ac]Ac-DOTATOC以评价疗效与毒性。

主要发现

  • 肝肿瘤对[68Ga]Ga-DOTATOC高摄取、对[18F]F-FDG无摄取,证实为高分化表型;[225Ac]Ac-DOTATOC治疗组总生存期较未标记DOTATOC组显著延长,240 kBq组53天(p=0.0001)、2×120 kBq组58天(p<0.0001)vs 未标记DOTATOC组28天;血液检查示治疗后白细胞计数一过性中度下降,未观察到严重肝、肾毒性,与病理及辐射剂量学结果一致。

关键数值与推荐

  • 240 kBq组中位总生存53天(p=0.0001),2×120 kBq组58天(p<0.0001),未标记DOTATOC组28天。
  • [68Ga]Ga-DOTATOC高摄取、[18F]F-FDG无摄取,证实肝肿瘤为高分化表型。
  • 治疗后白细胞计数一过性中度下降,未观察到严重肝、肾毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Although peptide radionuclide therapy (PRRT) using a somatostatin analog (SSA) radiolabeled with a beta- emitter: [177Lu]Lu-DOTATATE has shown a good clinical efficacy in neuroendocrine tumors (NETs), most of the patients only achieved tumoral stabilization and rare but severe long-term hematological toxicities have been reported. One of the promising options to improve PRRT is targeted alpha therapy. It is therefore essential to propose animal models that can mimic systemic spread disease, especially microscopic disease such as early stage of NET liver metastases to explore targeted alpha therapy. Herein, we report the evaluation of efficacy and toxicity of [225Ac]Ac-DOTATOC in an original preclinical murine model simulating the development of well-characterized liver metastases of pancreatic NETs with SSTR overexpression. METHODS: A mouse model of liver metastases of pancreatic NETs was developed by intraportal injection of AR42J cells and explored using [68 Ga]Ga-DOTATOC and [18F]F-FDG PET/MRI. Biodistribution study and radiation dosimetry of [225Ac]Ac-DOTATOC were determined in subcutaneous tumor-bearing NMRI-nude mice. Efficacy and toxicity were determined by intravenous injection of increasing activities of [225Ac]Ac-DOTATOC 10 days after intraportal graft. RESULTS: Liver tumors showed a high uptake of [68 Ga]Ga-DOTATOC and no uptake of [18F]F-FDG confirming the well-differentiated phenotype. All groups treated with [225Ac]Ac-DOTATOC showed a significant increase in overall survival compared with DOTATOC-treated mice, especially those treated with the highest activities: 53 days with 240 kBq (p = 0.0001), and 58 days with 2 × 120 kBq (p < 0.0001) vs 28 days with non-radiolabeled DOTATOC. On blood tests, a transient and moderate decreased in white blood cells count after treatment and no severe hepatic or renal toxicity were observed after treatment which was consistent with pathological and radiation dosimetry findings. CONCLUSION: [225Ac]Ac-DOTATOC exhibit a favorable efficacy and toxicity profile in a mouse model of liver micrometastatic pancreatic NET.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lugat A, Chouin N, Chocteau F, et al. Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases. Eur J Nucl Med Mol Imaging. 2024. PMID: 39269657. doi:10.1007/s00259-024-06918-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。